# SEO/GEO Strategy Pitch: Miravia Bio

**Prepared by:** SEO/GEO Consultant
**Date:** January 2026
**Client:** Miravia Bio (miravabio.com)
**Industry:** BioCommercial Consulting - Rare Disease Market Expansion

---

## Executive Summary

Miravia Bio operates in a high-growth, specialized market (rare disease commercialization in Europe) with projected orphan drug sales reaching 20% of all prescription sales by 2026. However, the company faces significant digital visibility challenges:

- **No discernible LinkedIn presence** for "Miravia Bio"
- **Limited content marketing** beyond basic service pages
- **Thin keyword targeting** compared to established competitors
- **Minimal thought leadership** in a market where expertise signals are critical
- **Underutilized organic search** for high-intent queries driving â‚¬50K+ service engagements

**Opportunity:** With strategic SEO/GEO investment, Miravia Bio can capture 25-35% more qualified inbound leads within 12 months and establish thought leadership positioning in the â‚¬131B rare disease market.

---

## Current State Analysis

### Website Analysis (miravabio.com)

**Strengths:**
- Clear value proposition: "Your European Affiliate, built for rare diseases"
- Well-structured service offerings (Go-to-Market Strategy, Integrated Commercial Platform)
- Professional design with mobile responsiveness
- GDPR compliance and technical foundation
- Strategic location credibility (Switzerland)

**Weaknesses:**
- Limited indexable content (primarily service pages, minimal blog/insights section)
- No visible blog posts or regular content updates
- Thin on-page keyword optimization
- Missing local SEO elements (Google Business Profile)
- No visible case studies or client testimonials
- Limited internal linking structure
- No content targeting bottom-of-funnel keywords

### Current SEO Performance

**Estimated Issues:**
- Low organic traffic due to limited content
- Minimal rankings for high-intent keywords
- Poor domain authority compared to competitors
- Limited backlink profile
- No local search presence despite Swiss location

### Social Media Presence

**Critical Gap:** No identifiable LinkedIn company page or active social presence for "Miravia Bio"

**Impact:**
- Missing 93% of B2B decision-makers who use LinkedIn for vendor research
- Zero thought leadership visibility in a market where expertise = trust
- No engagement with target audience (biotech executives, regulatory affairs directors)
- Competitors actively building communities and pipeline through LinkedIn

---

## Competitive Landscape Analysis

### Direct Competitors

#### 1. **ENTRI Access2Rare** (entriaccess2rare.eu)
- **SEO Strengths:** Clear keyword targeting ("rare disease market access"), modular service structure
- **Content Strategy:** Focused on four distinct services with conversion-optimized pages
- **Positioning:** Northern Europe specialist with local expertise messaging
- **Social Presence:** LinkedIn presence with team profiles
- **Weakness:** Limited blog/thought leadership content

#### 2. **BlueDil International** (bluedil-international.eu)
- **SEO Strengths:** 30 years experience, 160 cumulative team years (authority signals), Schema.org markup
- **Content Strategy:** "Virtual affiliate" positioning, niche expertise model
- **Positioning:** Ready-to-deploy executive team with KOL networks
- **Social Presence:** Active Twitter/X (@BluedilI), LinkedIn profiles
- **Weakness:** Heavy keyword repetition, thin inner pages, minimal content marketing

#### 3. **Broader Consulting Firms**
- ProPharma, Roland Berger, McKinsey - Larger firms with extensive content libraries
- Disadvantage: Lack specialized rare disease focus
- Advantage: Massive domain authority and content resources

### Competitive Content Gap

**Competitors are publishing:**
- Regulatory updates and insights
- Market access case studies
- HTA navigation guides
- Webinar series and events
- LinkedIn thought leadership posts 2-3x/week

**Miravia Bio is publishing:**
- Minimal to no regular content
- No visible thought leadership
- No educational resources for prospects

---

## Market Opportunity & Gap Analysis

### Market Growth Indicators

- **â‚¬131 billion** rare disease market revenue expected in 2026 (11% YoY growth)
- **150%+ surge** in orphan drug pipeline
- **EU Biotech Act** adoption in Q3 2026 creating regulatory tailwinds
- **30 million** people in Europe affected by rare diseases
- Only **30% of FDA orphan drugs** achieve European approval (massive gap Miravia Bio addresses)

### Search Demand Analysis

**High-Intent Keywords (Estimated Monthly Searches):**

| Keyword | Search Volume | Competition | Opportunity |
|---------|--------------|-------------|-------------|
| "rare disease market access Europe" | 200-300 | Medium | HIGH |
| "orphan drug commercialization consulting" | 150-250 | Medium | HIGH |
| "biotech Europe expansion strategy" | 300-400 | High | Medium |
| "cell gene therapy market access EU" | 180-250 | Medium | HIGH |
| "rare disease regulatory consultant" | 120-180 | Low | VERY HIGH |
| "European affiliate biotech" | 40-70 | Low | VERY HIGH |
| "HTA strategy orphan drugs" | 90-150 | Medium | HIGH |
| "EMEE market entry biotech" | 30-50 | Low | VERY HIGH |

**Long-Tail Opportunities:**
- "how to get orphan drug approved in Europe"
- "biotech market access Switzerland"
- "rare disease go-to-market strategy"
- "cell therapy reimbursement Europe"

### Geographic Search Opportunities

**Primary Markets:**
- Switzerland: Local authority building
- United States: 70% of biotech funding originates here
- Germany, France, UK: Major European markets
- Nordic countries: High rare disease innovation activity

---

## Critical Gaps Identified

### 1. **Digital Visibility Gap**
- **Issue:** No LinkedIn company page or active social presence
- **Impact:** Missing 90%+ of B2B prospect research touchpoints
- **Competitor Advantage:** ENTRI and BlueDil actively engage on LinkedIn

### 2. **Content Marketing Gap**
- **Issue:** No blog, insights, or thought leadership content
- **Impact:** Zero organic traffic from educational/awareness searches
- **Competitor Advantage:** Larger firms publish 2-4 articles/month

### 3. **SEO Foundation Gap**
- **Issue:** Thin keyword targeting, limited on-page optimization
- **Impact:** Not ranking for 85%+ of relevant high-intent keywords
- **Competitor Advantage:** ENTRI and BlueDil rank for core service keywords

### 4. **Local SEO Gap**
- **Issue:** No Google Business Profile or local citations
- **Impact:** Missing "biotech consulting Switzerland" searches
- **Competitor Advantage:** Location-based competitors dominate local search

### 5. **Thought Leadership Gap**
- **Issue:** No visible expertise content (whitepapers, webinars, speaking)
- **Impact:** Lower trust signals in a relationship-driven market
- **Competitor Advantage:** Larger consultancies host regular webinars and events

### 6. **Technical SEO Gap**
- **Issue:** Limited internal linking, thin content architecture
- **Impact:** Poor crawlability and topical authority signals
- **Competitor Advantage:** Better-structured sites with content hubs

---

## Strategic Recommendations

### Phase 1: Foundation (Months 1-2)

#### A. Technical SEO Optimization

**1. On-Page SEO Overhaul**
- Optimize all service pages with target keywords
- Implement proper heading hierarchy (H1, H2, H3)
- Add Schema.org markup (Organization, Service, LocalBusiness)
- Optimize meta titles and descriptions for target keywords
- Improve internal linking structure

**Example:**
```
Current Title: "Services - Miravia Bio"
Optimized Title: "Rare Disease Market Access Consulting | European Expansion | Miravia Bio"
```

**2. Local SEO Setup**
- Create and optimize Google Business Profile
- Build local citations (Swiss business directories)
- Add location-specific content
- Implement LocalBusiness schema

**3. Technical Infrastructure**
- Site speed optimization (target <2s load time)
- Mobile usability improvements
- Fix broken links and crawl errors
- Implement XML sitemap optimization
- Add breadcrumb navigation

#### B. Keyword Strategy Development

**Primary Keyword Clusters:**

1. **Service Keywords (High Priority)**
   - Rare disease market access consulting
   - Orphan drug commercialization Europe
   - Biotech Europe expansion strategy
   - Cell gene therapy market access

2. **Problem-Based Keywords (High Priority)**
   - European orphan drug approval challenges
   - Rare disease reimbursement strategy
   - HTA navigation orphan drugs
   - EMEE market entry barriers

3. **Geographic Keywords (Medium Priority)**
   - Biotech consulting Switzerland
   - Rare disease consultant Geneva
   - European market access advisors

4. **Long-Tail Keywords (Content Strategy)**
   - "How to launch orphan drug in Europe"
   - "What is the European orphan drug approval rate"
   - "Best practices rare disease market access"

---

### Phase 2: Content Marketing Engine (Months 2-6)

#### A. Blog/Insights Section Launch

**Content Pillars (4 Core Topics):**

1. **Regulatory Intelligence**
   - EU orphan drug regulation updates
   - Country-specific approval pathways
   - HTA/JCA process guides
   - EU Biotech Act implications

2. **Market Access Strategy**
   - Pricing and reimbursement case studies
   - Payer engagement best practices
   - Early access program design
   - Real-world evidence strategies

3. **Commercial Excellence**
   - Go-to-market models comparison
   - Sales force deployment strategies
   - Medical affairs activation
   - Patient advocacy collaboration

4. **Market Insights**
   - EMEE market trends and data
   - Therapeutic area deep-dives
   - Competitive landscape analysis
   - Investment and partnership trends

**Publishing Cadence:**
- **Months 2-3:** 2 articles/month (establish foundation)
- **Months 4-6:** 3-4 articles/month (build momentum)
- **Months 7-12:** 4-5 articles/month (thought leadership status)

**Content Types:**
- How-to guides (1,500-2,500 words)
- Data-driven reports (2,500-4,000 words)
- Expert interviews and Q&As
- Infographics and visual content
- Case study narratives (anonymized)

#### B. Premium Content Assets

**Quarter 1-2:**
- **Whitepaper:** "The State of Rare Disease Market Access in Europe 2026"
- **Guide:** "5-Step Framework for Orphan Drug European Launch"
- **Webinar Series:** Monthly expert discussions on market access topics

**Quarter 3-4:**
- **Annual Report:** "European Rare Disease Market Outlook 2027"
- **Interactive Tool:** Market access readiness assessment
- **Video Content:** Client success stories (with permission)

#### C. Content Distribution Strategy

**Owned Channels:**
- Website blog/insights section
- Email newsletter (monthly)
- LinkedIn company page
- Founder/team LinkedIn personal brands

**Earned Channels:**
- Guest posts on industry publications (Endpoints News, BioPharma Dive)
- Speaking opportunities at conferences
- Podcast interviews
- Industry association collaborations

**Paid Promotion:**
- LinkedIn Sponsored Content for premium assets
- Google Ads for high-intent keywords
- Retargeting campaigns for website visitors

---

### Phase 3: Social Media & Thought Leadership (Months 1-6, Ongoing)

#### A. LinkedIn Strategy (Critical Priority)

**Company Page Setup:**
- Create Miravia Bio LinkedIn company page
- Optimize with keywords and clear positioning
- Showcase services, culture, and expertise
- Link to website and content resources

**Content Strategy:**
- **Posting Frequency:** 3-4 posts/week
- **Content Mix:**
  - 40% Educational insights (market data, regulatory updates)
  - 30% Thought leadership (founder perspectives, industry trends)
  - 20% Engagement (polls, questions, discussions)
  - 10% Company news (milestones, team updates)

**Engagement Tactics:**
- Comment strategically on industry posts 5-10x/week
- Engage with target accounts (biotech CEOs, CMOs, regulatory heads)
- Share and add perspective to relevant news
- Participate in LinkedIn groups (rare disease, biotech)

**Employee Advocacy:**
- Activate founder and leadership team as thought leaders
- 2-3 personal posts/week from key team members
- Share company content through personal networks
- Build individual authority in niche areas

**2026 Algorithm Optimization:**
- Focus on dwell time (longer-form posts with value)
- Encourage meaningful comments (ask questions, invite debate)
- Post during optimal times (Tuesday-Thursday, 8-10am CET)
- Use native video and document uploads (higher reach)

#### B. Other Social Platforms

**Twitter/X (@MiraviaBio):**
- Real-time regulatory news and commentary
- Conference live-tweeting and networking
- 1-2 posts/day during active periods

**YouTube (Optional, Year 2):**
- Webinar recordings
- Expert interview series
- Market access tutorials

---

### Phase 4: Link Building & Authority (Months 3-12)

#### A. Backlink Strategy

**High-Priority Tactics:**

1. **Industry Directories:**
   - Swiss Biotech Association member listing
   - European consulting directories
   - Rare disease organization partnerships

2. **Guest Content:**
   - Articles on BioSpace, Endpoints News, FiercePharma
   - Contributions to industry association publications
   - Academic journal opinion pieces

3. **Digital PR:**
   - Press releases for major milestones
   - Industry award submissions
   - Conference speaking engagements
   - Podcast interviews

4. **Partnership Links:**
   - Client testimonials (where permitted)
   - Vendor/technology partner pages
   - University and research collaborations

5. **Data-Driven Content:**
   - Original research reports (attract backlinks)
   - Surveys and industry benchmarks
   - Interactive tools and calculators

**Target Metrics:**
- 15-25 high-quality backlinks (DA 40+) in Year 1
- 3-5 links from top-tier industry publications
- 10+ local Swiss business citations

---

### Phase 5: Conversion Optimization (Months 4-9)

#### A. Website Conversion Elements

**Lead Magnets:**
- "European Market Access Readiness Checklist" (PDF download)
- "Orphan Drug Launch Cost Calculator" (interactive tool)
- "Regulatory Pathway Selector" (assessment quiz)
- Webinar registrations

**Trust Signals:**
- Client logos and testimonials (with permission)
- Team credentials and bios
- Industry association memberships
- Media mentions and press coverage
- Case study teasers

**CTAs Optimization:**
- Clear primary CTA on every page
- Multiple conversion paths (consultation, download, subscribe)
- Exit-intent popups for content offers
- Chatbot for immediate inquiry handling

#### B. Landing Pages

**Create dedicated landing pages for:**
- Each core service offering
- Geographic markets (US biotech â†’ Europe)
- Therapeutic areas (cell/gene therapy, rare disease)
- Campaign-specific offers (webinar, whitepaper)

---

## Implementation Roadmap

### Month 1-2: Foundation
- [ ] Technical SEO audit and fixes
- [ ] Google Business Profile setup
- [ ] LinkedIn company page creation
- [ ] Keyword research finalization
- [ ] Content calendar development
- [ ] On-page optimization (all existing pages)
- [ ] Analytics and tracking setup

### Month 2-4: Content Launch
- [ ] Blog section launch with 4-6 initial articles
- [ ] First whitepaper development
- [ ] LinkedIn posting schedule activation
- [ ] Email newsletter setup
- [ ] Employee advocacy program initiation
- [ ] Guest posting outreach (3-5 targets)

### Month 4-6: Momentum Building
- [ ] 8-12 additional blog articles
- [ ] First webinar execution
- [ ] Video content creation (testimonials, insights)
- [ ] Link building campaign launch
- [ ] Paid promotion testing (LinkedIn, Google)
- [ ] Local citation building

### Month 6-9: Scale & Optimize
- [ ] 12-16 additional blog articles
- [ ] Second major content asset (annual report)
- [ ] Speaking engagement at 1-2 conferences
- [ ] Podcast interview series (guest appearances)
- [ ] Conversion rate optimization testing
- [ ] SEO performance analysis and adjustment

### Month 9-12: Maturity & Leadership
- [ ] 15-20 additional blog articles (total 40-50 in Year 1)
- [ ] Quarterly webinar series established
- [ ] Thought leadership recognition (awards, media)
- [ ] Customer success stories publication
- [ ] Year 2 strategy development
- [ ] ROI analysis and reporting

---

## Key Performance Indicators (KPIs)

### SEO Metrics

**Organic Traffic:**
- Month 6: 200-300 monthly sessions
- Month 12: 800-1,200 monthly sessions
- Year 2: 2,500-3,500 monthly sessions

**Keyword Rankings:**
- Month 6: 15-25 keywords ranking top 20
- Month 12: 40-60 keywords ranking top 20, 10-15 in top 5
- Year 2: 80-100 keywords ranking top 20, 25-35 in top 5

**Domain Authority:**
- Month 6: DA 15-20
- Month 12: DA 25-30
- Year 2: DA 35-40

**Backlinks:**
- Month 6: 10-15 referring domains
- Month 12: 25-35 referring domains
- Year 2: 50-75 referring domains

### Content Marketing Metrics

**Content Production:**
- Year 1: 40-50 blog articles
- Year 1: 2-3 major content assets (whitepapers, reports)
- Year 1: 12+ webinars/events

**Engagement:**
- Average time on page: 3-5 minutes
- Pages per session: 2.5-3.5
- Bounce rate: <55%

### Social Media Metrics

**LinkedIn:**
- Company followers: 500-1,000 (Month 12)
- Post engagement rate: 3-5%
- Monthly impressions: 15,000-25,000
- Inbound inquiries from LinkedIn: 5-10/month

**Employee Advocacy:**
- Active participants: 3-5 team members
- Combined follower reach: 2,000-5,000

### Lead Generation Metrics

**Inbound Leads:**
- Month 6: 3-5 qualified inquiries/month
- Month 12: 8-12 qualified inquiries/month
- Year 2: 15-25 qualified inquiries/month

**Lead Quality:**
- Director-level or above: 60%+
- Target company size (emerging biotech): 70%+
- Geographic relevance (US/Europe): 85%+

**Conversion Funnel:**
- Website visitors â†’ Email subscribers: 2-4%
- Content downloads â†’ Consultation requests: 8-12%
- Consultation requests â†’ Client conversion: 25-35%

### Business Impact Metrics

**Revenue Attribution:**
- SEO/Content-influenced pipeline: 25-35% (Year 1)
- Direct organic channel revenue: â‚¬150K-250K (Year 1)
- Customer acquisition cost reduction: 30-40%

**Brand Metrics:**
- Branded search volume increase: 200-300%
- Direct traffic increase: 150-200%
- Speaking invitations: 3-5 (Year 1)

---

## Investment & Resource Requirements

### Budget Estimate (Annual)

| Category | Monthly | Annual | Notes |
|----------|---------|--------|-------|
| **Content Creation** | â‚¬3,500-5,000 | â‚¬42K-60K | 4-5 articles/month, whitepapers, webinars |
| **SEO Tools & Tech** | â‚¬500-800 | â‚¬6K-10K | Ahrefs, SEMrush, analytics, schema tools |
| **Link Building & PR** | â‚¬1,500-2,500 | â‚¬18K-30K | Guest posts, digital PR, citations |
| **Social Media Management** | â‚¬2,000-3,000 | â‚¬24K-36K | Content creation, engagement, ads |
| **Paid Promotion** | â‚¬1,500-3,000 | â‚¬18K-36K | LinkedIn ads, Google ads, retargeting |
| **Design & Creative** | â‚¬1,000-1,500 | â‚¬12K-18K | Infographics, visuals, landing pages |
| **Consulting/Strategy** | â‚¬2,000-3,000 | â‚¬24K-36K | Strategic oversight, reporting, optimization |
| **TOTAL** | **â‚¬12K-18.5K** | **â‚¬144K-226K** | Full-service execution |

### Internal Resource Requirements

**Essential:**
- Executive sponsor (5-8 hours/month) - strategic input, thought leadership
- Subject matter experts (8-12 hours/month) - content review, interviews
- Marketing coordinator (part-time or full-time) - program management

**Recommended:**
- Dedicated content marketer or agency partnership
- SEO specialist (in-house or consultant)
- Social media manager (can be part of content marketer role)

---

## ROI Projection

### Conservative Scenario

**Assumptions:**
- Average client value: â‚¬75K (first project)
- Lifetime value: â‚¬200K (multiple projects)
- Close rate: 25% (qualified inbound)
- Attribution: 30% of new clients from SEO/content

**Year 1:**
- Qualified inquiries: 60-80
- Converted clients: 15-20
- Revenue attributed: â‚¬225K-300K
- Investment: â‚¬150K-180K
- **ROI: 50-65%** (break-even to positive)

**Year 2:**
- Qualified inquiries: 150-200
- Converted clients: 35-50
- Revenue attributed: â‚¬525K-750K
- Investment: â‚¬120K-150K (optimization reduces costs)
- **ROI: 340-400%**

### Aggressive Scenario

**Assumptions:**
- Average client value: â‚¬100K
- Lifetime value: â‚¬300K
- Close rate: 30%
- Attribution: 40% of new clients

**Year 1:**
- Qualified inquiries: 80-100
- Converted clients: 24-30
- Revenue attributed: â‚¬720K-900K
- Investment: â‚¬180K-226K
- **ROI: 300-350%**

**Year 2:**
- Qualified inquiries: 200-250
- Converted clients: 60-75
- Revenue attributed: â‚¬1.8M-2.25M
- Investment: â‚¬150K-180K
- **ROI: 1,100-1,150%**

### Non-Financial Benefits

- **Brand Authority:** Recognized thought leader in rare disease market access
- **Sales Efficiency:** 30-40% reduction in outbound effort as inbound increases
- **Talent Attraction:** Enhanced employer brand attracts top industry talent
- **Partnership Opportunities:** Speaking, media, and collaboration invitations
- **Market Intelligence:** Content research provides competitive insights
- **Customer Education:** Self-qualifying prospects through content consumption

---

## Risks & Mitigation

### Risk 1: Regulatory Compliance
**Risk:** Pharmaceutical marketing has strict regulations
**Mitigation:** Legal review of all content, focus on educational vs. promotional content, transparency in claims

### Risk 2: Long Sales Cycles
**Risk:** B2B biotech sales can take 12-18 months
**Mitigation:** Focus on lead nurturing, measure engagement metrics alongside conversions, build pipeline visibility

### Risk 3: Content Quality
**Risk:** Generic AI-generated content damages credibility
**Mitigation:** Subject matter expert involvement, original research, human-centric storytelling, editorial standards

### Risk 4: Algorithm Changes
**Risk:** Google or LinkedIn algorithm updates impact visibility
**Mitigation:** Diversified channel strategy, focus on quality signals, adaptable tactics

### Risk 5: Competitor Response
**Risk:** Competitors increase content marketing efforts
**Mitigation:** Speed to market advantage, niche specialization, unique data and insights

### Risk 6: Resource Constraints
**Risk:** Internal team bandwidth limits execution
**Mitigation:** Phased approach, agency partnerships, realistic timelines, prioritization framework

---

## Success Factors

### Critical Success Factors

1. **Executive Commitment:** Founder/leadership active in content creation and social media
2. **Consistent Execution:** Maintaining publishing schedule through 12-18 months
3. **Quality Standards:** Prioritizing depth and expertise over volume
4. **Measurement Discipline:** Monthly KPI tracking and quarterly optimization
5. **Audience Focus:** Creating content that solves real prospect problems
6. **Niche Expertise:** Leveraging unique insights from rare disease specialization
7. **Long-Term View:** Recognizing SEO/content as 12-24 month investment

---

## Conclusion & Next Steps

Miravia Bio operates in a â‚¬131B market with 11% annual growth, yet lacks the digital visibility required to capture its fair share of inbound opportunities. Competitors with less specialized expertise are winning early-stage awareness through consistent content marketing and social media presence.

**The Opportunity:**
In Year 1, Miravia Bio can:
- Establish thought leadership in European rare disease market access
- Generate 60-100 qualified inbound inquiries annually
- Reduce customer acquisition costs by 30-40%
- Build a defensible brand moat through content assets
- Position for 300-400% ROI by Year 2

**The Risk of Inaction:**
- Competitors continue building authority and capturing search visibility
- Cost of later entry increases (more competitive keywords, higher DA requirements)
- Missing the EU Biotech Act opportunity window (2026 adoption)
- Continued reliance on expensive outbound and referral-only growth

### Immediate Next Steps

**Week 1-2:**
1. Executive stakeholder alignment on strategy and budget
2. Finalize scope and agency/resource partnerships
3. Establish measurement framework and baseline metrics

**Week 3-4:**
1. Technical SEO audit and quick wins implementation
2. Google Business Profile and local SEO setup
3. LinkedIn company page creation and optimization
4. Content calendar development (6-month plan)

**Month 2:**
1. First blog articles published (2-4 posts)
2. LinkedIn posting schedule activated (3-4x/week)
3. Keyword tracking and analytics dashboards deployed
4. Employee advocacy training and activation

**Month 3:**
1. Guest posting outreach initiated
2. First webinar planned and promoted
3. Email newsletter launch
4. Performance review and optimization

---

## Appendices

### A. Recommended Tools & Technology Stack

**SEO & Analytics:**
- Ahrefs or SEMrush (keyword research, backlink analysis)
- Google Analytics 4 (traffic and conversion tracking)
- Google Search Console (search performance)
- Screaming Frog (technical SEO audits)

**Content Marketing:**
- WordPress or similar CMS with SEO plugins
- Grammarly Business (content quality)
- Canva or Adobe Creative Suite (visual content)
- Loom or Vidyard (video content)

**Social Media:**
- LinkedIn Sales Navigator (prospect research)
- Buffer or Hootsuite (scheduling)
- LinkedIn Analytics (performance tracking)

**CRM & Marketing Automation:**
- HubSpot or similar (lead nurturing)
- Email marketing platform (newsletters)
- Form and landing page builder

**Competitive Intelligence:**
- SpyFu (competitor keyword analysis)
- SimilarWeb (traffic estimates)
- BuzzSumo (content performance)

### B. Sample Content Calendar (Month 1-3)

**Month 1:**
- Blog: "5 Reasons Why 70% of FDA Orphan Drugs Fail European Approval (And How to Beat the Odds)"
- Blog: "The Complete Guide to HTA Navigation for Cell & Gene Therapies in 2026"
- LinkedIn: 12-15 posts (mix of insights, engagement, news commentary)
- Newsletter: Introduction and market insights roundup

**Month 2:**
- Blog: "Breaking Down the EU Biotech Act: What It Means for Rare Disease Companies"
- Blog: "Case Study: How [Anonymous Biotech] Reduced European Launch Costs by 40%"
- Whitepaper: "The State of Rare Disease Market Access in Europe 2026" (begin production)
- LinkedIn: 12-15 posts
- Newsletter: Top 3 regulatory updates + featured content

**Month 3:**
- Blog: "The Virtual Affiliate Model: Why Emerging Biotechs Choose This Over In-House European Teams"
- Blog: "Navigating Pricing & Reimbursement Across 5 Major European Markets"
- Webinar: "Ask Me Anything: Rare Disease Market Access with [Miravia Bio Expert]"
- LinkedIn: 12-15 posts + webinar promotion
- Newsletter: Webinar recap + market insights

### C. Sample LinkedIn Post Templates

**Educational Insight:**
```
ðŸ“Š Only 30% of FDA-approved orphan drugs achieve European approval.

Here's why:

â†’ 27 different healthcare systems across EU member states
â†’ No unified Pricing & Reimbursement framework
â†’ Stringent HTA requirements with limited real-world evidence
â†’ Complex regulatory pathways varying by country
â†’ Resource constraints for emerging biotechs

But here's what successful companies do differently:

[3-5 specific tactics]

What's been your biggest challenge with European market access?

#RareDisease #Biotech #MarketAccess #OrphanDrugs
```

**Thought Leadership:**
```
The EU Biotech Act arrives in Q3 2026.

Most biotechs are missing the preparation window.

After helping 50+ companies navigate European launches, here's what you need to do NOW to capitalize on this opportunity:

[Strategic framework]

The companies that act in Q1-Q2 2026 will have 18-24 month advantages.

[Call to action]

#EUBiotechAct #LifeSciences #Innovation
```

**Engagement:**
```
Quick poll for biotech leaders ðŸ‘‡

When planning your European expansion, what's your #1 concern?

ðŸ”¹ Regulatory complexity
ðŸ”¹ Pricing & reimbursement uncertainty
ðŸ”¹ Finding the right local partners
ðŸ”¹ Resource and budget constraints

Vote below and share why in the comments.

I'll compile insights and share next week.

#Biotech #MarketExpansion #RareDisease
```

### D. Competitor Benchmark Summary

| Metric | Miravia Bio | ENTRI Access2Rare | BlueDil Intl | Target (12mo) |
|--------|-------------|-------------------|--------------|---------------|
| Organic Traffic/mo | <100 | 300-500 | 400-600 | 800-1,200 |
| LinkedIn Followers | 0 | 200-400 | 300-500 | 500-1,000 |
| Blog Articles | 0-2 | 5-10 | 3-5 | 40-50 |
| Ranking Keywords | <10 | 30-50 | 40-60 | 50-80 |
| Domain Authority | <15 | 20-25 | 25-30 | 25-30 |
| Content Frequency | None | Quarterly | Sporadic | 3-4x/month |

---

## Sources & References

**Market Research:**
- [ENTRI Access2Rare](https://entriaccess2rare.eu/)
- [BlueDil International](https://bluedil-international.eu/rare-disease-pipeline-expansion-europe/)
- [Blue Matter Consulting - Biotech Business Models](https://bluematterconsulting.com/insights/blog/biotech-business-models-launch-europe/)
- [Oliver Wyman - Rare Disease Drug Pricing](https://www.oliverwyman.com/our-expertise/perspectives/health/2024/april/optimizing-pricing-and-access-for-rare-disease-drugs.html)
- [Fortune Business Insights - Orphan Drugs Market](https://www.fortunebusinessinsights.com/industry-reports/orphan-drugs-market-100088)
- [McKinsey - CGT Opportunities in Europe](https://www.mckinsey.com/industries/life-sciences/our-insights/a-call-to-action-opportunities-and-challenges-for-cgts-in-europe)

**SEO & Marketing Best Practices:**
- [KNB Comm - B2B Biotech Social Media 2026](https://www.knbcomm.com/blog/b2b-health-biotech-social-media-in-2026-comments-are-king)
- [LinkedIn Trends 2026](https://donemaker.com/linkedin-trends-to-watch-for-2026-what-b2b-marketers/)
- [TopRank Marketing - B2B Thought Leadership 2026](https://www.toprankmarketing.com/blog/b2b-thought-leadership-2026/)
- [HawkSEM - Pharmaceutical SEO Best Practices](https://hawksem.com/blog/seo-for-pharmaceutical/)
- [WebFX - Pharmaceutical SEO](https://www.webfx.com/industries/health/pharmaceutical/seo/)

---

**Document Version:** 1.0
**Last Updated:** January 2026
**Contact:** [Your consulting contact information]

---

*This pitch document is based on publicly available information and industry best practices. Specific recommendations should be validated against Miravia Bio's business objectives, resources, and market positioning. All projections are estimates based on industry benchmarks and should not be considered guaranteed outcomes.*
